会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • TEMPERATURE SETTING METHOD OF THERMAL PROCESSING PLATE, COMPUTER-READABLE RECORDING MEDIUM RECORDING PROGRAM THEREON, AND TEMPERATURE SETTING APPARATUS FOR THERMAL PROCESSING PLATE
    • 热处理板的温度设定方法,计算机可读记录介质记录程序及温度设定装置
    • US20080116195A1
    • 2008-05-22
    • US11934303
    • 2007-11-02
    • Megumi JyousakaYoshitaka Konishi
    • Megumi JyousakaYoshitaka Konishi
    • H05B1/02
    • G05D23/1932H01L21/67248
    • In the present invention, a thermal plate of a PEB unit is divided into a plurality of thermal plate regions, and a temperature is settable for each of the thermal plate regions. A temperature correction value for adjusting the temperature within the thermal plate is settable for each of the thermal plate regions of the thermal plate. The line widths within the substrate which has been subjected to the photolithography process are measured, and an improvement in-plane tendency Za improved by change of the temperature settings is subtracted from an in-plane tendency Z of the measured line widths within the substrate to calculate an in-plane tendency Zb of the line widths within the substrate after change of temperature settings. The improvement in-plane tendency Za is calculated using the following expression. Za=−1×α×MT (α: a resist heat sensitivity, M: a calculation model, and T: temperature correction values for thermal plate regions)
    • 在本发明中,将PEB单元的热板分割为多个热板区域,并且可以对每个热板区域设定温度。 用于调节热板内的温度的温度校正值可针对热板的每个热板区域而设定。 测量已进行了光刻处理的基板内的线宽,并从基板内的被测线宽度的面内倾向Z中减去由温度设定的变化而提高的面内倾向Za, 在温度设置更改后,计算衬底内线宽的面内倾向Zb。 使用以下表达式计算平面内倾向Za的改善。 <?in-line-formula description =“In-line Formulas”end =“lead”?> Za = -1xalphaxMT(α:抗蚀剂热敏性,M:计算模型,T:热板区域的温度校正值 )<?in-line-formula description =“In-line Formulas”end =“tail”?>
    • 6. 发明授权
    • Heterocyclic compounds
    • 杂环化合物
    • US6001830A
    • 1999-12-14
    • US189843
    • 1998-11-12
    • Sung Jai LeeYoshitaka KonishiOrest Taras MacinaKigen KondoDingwei Tim YuManton Rodgers FriersonMasafumi Sugitani
    • Sung Jai LeeYoshitaka KonishiOrest Taras MacinaKigen KondoDingwei Tim YuManton Rodgers FriersonMasafumi Sugitani
    • A61K31/505A61P1/16A61P7/02A61P9/00A61P9/08A61P9/10A61P9/12A61P11/00A61P11/08A61P13/02A61P15/00A61P25/28A61P29/00A61P37/04A61P43/00C07D487/04C07D495/04A61K31/50
    • C07D487/04C07D495/04
    • The compounds of the formula: ##STR1## wherein ring ##STR2## is a hetero ring containing nitrogen atom, optionally selected from ##STR3## n is 0-2; Y is bond or alkylene;Z is bond, alkylene or vinylene;E is(i) 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, 1 or 2 N atoms, 1 or 2 O atoms or 1 S atom,(ii) 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring, or(iii) --OR.sup.4 (in which R.sup.4 is hydrogen atom, alkyl or alkyl substituted by a hydroxy group);Cyc is 5-7 membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, 1 or 2 N atoms or 5-7 membered, unsaturated or partially saturated, monocyclic carbocyclic ring;R.sup.1 is H or alkyl;R.sup.2 is H, alkyl, alkoxy or halogen atom;R.sup.3 is H, alkyl, alkoxy or --COOR.sup.5 (in which R.sup.5 is H or alkyl);with the proviso that(1) a Cyc ring should not bond to Z through a nitrogen atom in the Cyc ring when Z is vinylene and that(2) Y is not a single bond, when E is --OR.sup.4 ;or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof; have inhibitory effect on cGMP-PDE, or additionally on TXA.sub.2 synthetase.
    • 下式的化合物:其中环是含氮原子的杂环,任选地选自n是0-2; Y是键或亚烷基; Z是键,亚烷基或亚乙烯基; E是(i)含有1或2个N原子,1或2个O原子或1个S原子的4-15元,不饱和,部分饱和或完全饱和的单或双环杂环,(ii)4-15 或(iii)-OR4(其中R4为氢原子,被羟基取代的烷基或烷基);或(iii)-OR4(其中R4为氢原子,被羟基取代的烷基或烷基); 环是含有杂原子,1或2个N原子或5-7元不饱和或部分饱和的单环碳环的5-7元,不饱和,部分饱和或完全饱和的单环杂环; R1是H或烷基; R2是H,烷基,烷氧基或卤素原子; R3是H,烷基,烷氧基或-COOR5(其中R5是H或烷基); 条件是(1)当Z是亚乙烯基时,环环不应通过环中的氮原子与Z键合,并且(2)Y不是单键,当E是-OR4时; 或其药学上可接受的酸加成盐,其药学上可接受的盐或其水合物; 对cGMP-PDE或另外在TXA2合成酶具有抑制作用。
    • 8. 发明授权
    • 6,9-Methano-PGI2 analogues
    • US4479966A
    • 1984-10-30
    • US113502
    • 1980-01-21
    • Masaki HayashiYoshitaka KonishiYoshinobu Arai
    • Masaki HayashiYoshitaka KonishiYoshinobu Arai
    • A61K47/48C07C45/64C07C45/65C07C45/67C07C49/517C07C405/00C07D309/12C07C177/00C07C59/46
    • B82Y5/00A61K47/48969C07C405/0083C07C45/64C07C45/65C07C45/673C07C49/517C07D309/12Y02P20/55
    • Prostaglandin I.sub.2 analogues of the formula: ##STR1## [wherein the symbol between the carbon atoms in positions 5 and 6 represents a single or double bond, Y represents ethylene or trans-vinylene, R.sup.1 represents hydrogen, alkyl of 1 to 12 carbon atoms, aralkyl of 7 to 12 carbon atoms, cycloalkyl of 4 to 7 carbon atoms optionally substituted by alkyl of 1 to 4 carbon atoms, phenyl optionally substituted by chlorine, trifluoromethyl, alkyl of 1 to 4 carbon atoms or phenyl, a --C.sub.m H.sub.2m COOR.sup.7 group (wherein m represents an integer of from 1 to 12 and R.sup.7 represents alkyl of 1 to 4 carbon atoms), a --C.sub.n H.sub.2n OR.sup.8 group (wherein n represents an integer of from 2 to 12 and R.sup.8 represents hydrogen or alkyl of 1 to 4 carbon atoms) or a ##STR2## group (wherein R.sup.9 and R.sup.10 each represent alkyl of 1 to 4 carbon atoms and n is as hereinbefore defined), R.sup.2 represents hydrogen or a hydroxy-protecting group, R.sup.3 represents hydrogen or a hydroxy-protecting group which is eliminated under acidic conditions, R.sup.4 represents hydrogen, methyl or ethyl, R.sup.5 represents a single bond or alkylene of 1 to 4 carbon atoms optionally substituted by a chlorine atom (provided that, when R.sup.5 is alkylene substituted by chlorine, R.sup.6 represents hydrogen or alkyl) R.sup.6 represents hydrogen, alkyl or 1 to 8 carbon atoms, cycloalkyl of 4 to 7 carbon atoms optionally substituted by alkyl of 1 to 8 carbon atoms, or phenyl or phenoxy optionally substituted by cholrine, trifluoromethyl or alkyl of 1 to 4 carbon atoms, and when represents a double bond that bond is E, Z or a mixture thereof and when, represents a single bond, the absolute configuration of C.sub.6 is R, S or a mixture thereof] and, when R.sup.2 and R.sup.3 represent hydrogen, cyclodextrin clathrates of such acids and esters and, when R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, non-toxic salts thereof and, when R.sup.1 represents ##STR3## in which n, R.sup.9 and R.sup.10 are as hereinbefore defined, non-toxic acid addition salts thereof, are new compounds, possessing prostaglandin-like activity.
    • 9. 发明授权
    • Prostaglandin 12 analogues and their pharmaceutical compositions
    • 前列腺素12类似物及其药物组合物
    • US4399147A
    • 1983-08-16
    • US872635
    • 1978-01-26
    • Masaki HayashiYoshinobu AraiYoshitaka KonishiKatsuichi ShimojiShuichi OhuchidaHirohisa WakatsukaHiroyuki Ito
    • Masaki HayashiYoshinobu AraiYoshitaka KonishiKatsuichi ShimojiShuichi OhuchidaHirohisa WakatsukaHiroyuki Ito
    • C07D307/935A61K31/34A61K31/343A61P43/00C07C405/00C07D307/937A61K31/557
    • C07D307/937C07C405/00
    • Prostaglandin I.sub.2 analogues of the formula: ##STR1## [wherein X represents trans-vinylene or an ethylene group unsubstituted or substituted by a bromine atom at the C-5 position, Y represents trans-vinylene or ethylene, R.sup.1 represents hydrogen or an alkyl group containing from 1 to 12 carbon atoms, R.sup.2 represents hydrogen or methyl or ethyl, R.sup.3 represents a single bond or an alkylene group containing from 1 to 4 carbon atoms, R.sup.4 represents hydrogen, an alkyl group containing from 1 to 8 carbon atoms, a cycloalkyl group containing from 4 to 7 carbon atoms unsubstituted or substituted by at least one alkyl group containing from 1 to 8 carbon atoms, or a phenyl or phenoxy group unsubstituted or carrying at least one substituent selected from halogen atoms, the trifluoromethyl group and alkyl groups containing from 1 to 3 carbon atoms, and the wavy line attached to the carbon atoms in positions 6, 11 and 15 depicted in the formula represents .alpha.- or .beta.-configuration or mixtures thereof] are new compounds possessing pharmacological properties typical of prostaglandins, for example PGI.sub.2, and are more stable than PGI.sub.2.
    • 前列腺素I2类似物,具有下式:其中X表示反式亚乙烯基或未被取代或被C-5位上的溴原子取代的亚乙基,Y表示反式亚乙烯基或亚乙基,R 1表示氢或烷基 含有1至12个碳原子,R 2表示氢或甲基或乙基,R 3表示单键或含有1至4个碳原子的亚烷基,R 4表示氢,含有1至8个碳原子的烷基,环烷基 含有未取代或被至少一个含有1至8个碳原子的烷基取代的4至7个碳原子的基团,或未取代或携带至少一个选自卤素原子的取代基的苯基或苯氧基,三氟甲基和含有 1至3个碳原子,并且连接在式中描述的6,11和15位的碳原子上的波浪线代表α-或β-构型或其混合物] 是具有典型的前列腺素的药理学性质的新化合物,例如PGI 2,并且比PGI2更稳定。
    • 10. 发明授权
    • Prostaglandin I.sub.2 analogues
    • 前列腺素I2类似物
    • US4207332A
    • 1980-06-10
    • US944164
    • 1978-09-20
    • Masaki HayashiYoshinobu AraiKatsuichi ShimojiYoshitaka KonishiShuichi OhuchidaShinsuke Hashimoto
    • Masaki HayashiYoshinobu AraiKatsuichi ShimojiYoshitaka KonishiShuichi OhuchidaShinsuke Hashimoto
    • C07D307/935A61K31/34A61K31/343A61P43/00C07C405/00C07D307/937C07D307/93
    • C07D307/937C07C405/00
    • Prostaglandin analogues of the general formula: ##STR1## [wherein Y represents ethylene or trans-vinylene, R.sup.1 represents a group --C.sub.m H.sub.2m COOR.sup.5, --C.sub.n H.sub.2n OR.sup.6 or ##STR2## (wherein R.sup.5 represents an alkyl group containing from 1 to 4 carbon atoms, R.sup.6 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms, R.sup.7 and R.sup.8, which may be the same or different, each represents an alkyl group containing from 1 to 4 carbon atoms, m represents an integer of from 1 to 12 and n represents an integer of from 2 to 12), R.sup.2 represents a hydrogen atom or a methyl or ethyl group, R.sup.3 represents a single bond, or an alkylene group containing from 1 to 4 carbon atoms, R.sup.4 represents a hydrogen atom, an alkyl group containing from 1 to 8 carbon atoms, a cycloalkyl group containing from 4 to 7 carbon atoms in the ring, which may be unsubstituted or substituted by at least one alkyl group containing from 1 to 8 carbon atoms, or represents a phenyl or phenoxy group which may be unsubstituted or substituted by at least one chlorine atom, trifluoromethyl group or alkyl group containing from 1 to 3 carbon atoms, the wavy line attached to the carbon atoms in positions 11 and 15 represents .alpha.- or .beta.-configuration, or mixtures thereof, and the double bond between C.sub.5 -C.sub.6 is Z] and cyclodextrin clathrates thereof, and, when R.sup.1 represents a group ##STR3## in which n, R.sup.7 and R.sup.8 are as hereinbefore defined, non-toxic acid addition salts thereof, are new compounds and possess characteristic prostaglandin-like properties.
    • 前列腺素类似物具有以下通式:其中Y表示亚乙基或反式亚乙烯基,R1表示基团-CmH2mCOOR5,-CnH2nOR6或其中R5表示含有1至4个碳原子的烷基,R6表示 含有1至4个碳原子的氢原子或烷基,可以相同或不同的R 7和R 8各自表示含有1至4个碳原子的烷基,m表示1至12的整数,m表示1至12的整数, n表示2〜12的整数),R2表示氢原子或甲基或乙基,R3表示单键或含有1〜4个碳原子的亚烷基,R4表示氢原子,烷基 含有1至8个碳原子的环烷基,环中含有4至7个碳原子的环烷基,其可以是未取代的或被至少一个含有1至8个碳原子的烷基取代,或表示苯基或苯氧基, 可以是未取代的或未取代的 由至少一个氯原子,三氟甲基或含有1至3个碳原子的烷基取代,连接到位置11和15的碳原子的波浪线表示α或β构型,或其混合物,双键 C5-C6之间是Z]和环糊精包合物,当R1代表其中n,R7和R8如上所定义的基团“IMAGE”时,其无毒的酸加成盐是新的化合物,并且具有特征性的前列腺素 - 像属性。